Malignancy in children with trisomy 21

Oncologist

Volumn 14, Issue 2, 2009, Pages 164-173

  Rabin, Karen R ^a,c   Whitlock, James A ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c TEXAS CHILDREN S CANCER CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Acute megakaryoblastic leukemia; Down syndrome; GATA1 transcription factor; Janus kinase 2; Myeloproliferative disorders

Indexed keywords

ANTHRACYCLINE; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; IDARUBICIN; METHOTREXATE; PREDNISONE; RETINOL PALMITATE; TRANSCRIPTION FACTOR GATA 1; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER INCIDENCE; CANCER RISK; CARDIOMYOPATHY; CARDIOTOXICITY; CHEMOSENSITIVITY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DNA POLYMORPHISM; DOWN SYNDROME; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HEMATOPOIESIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; LOW DRUG DOSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PATHOGENESIS; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TREATMENT OUTCOME; TRISOMY 21;

ACUTE DISEASE; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; HUMANS; LEUKEMIA; NEOPLASMS;

EID: 64149129804     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0217     Document Type: Review

References (91)

1. Roizen NJ, Patterson D. Down's syndrome. Lancet 2003;361:1281-1289.
2. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000;355:165-169.
3. Patja K, Pukkala E, Sund R et al. Cancer incidence of persons with Down syndrome in Finland: A population-based study. Int J Cancer 2006;118: 1769-1772.
4. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: A population-based study. Lancet 2002;359:1019-1025.
5. Brewster HF, Cannon HE. Acute lymphatic leukemia: Report of a case in eleventh month mongolian idiot. New Orleans Med Surg J 1930;82:872-873.
6. Krivit W, Good RA. Simultaneous occurrence of mongolism and leukemia; report of a nationwide survey. AMA J Dis Child 1957;94:289-293.
7. Gamis AS, Woods WG, Alonzo TA et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: A report from the Children's Cancer Group Study 2891. J Clin Oncol 2003;21:3415-3422.
8. Hitzler JK. Acute megakaryoblastic leukemia in Down syndrome. Pediatr Blood Cancer 2007;49(7 suppl):1066-1069.
9. Creutzig U, Reinhardt D, Diekamp S et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005;19:1355-1360.
10. Zipursky A, Thorner P, De Harven E et al. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res 1994;18:163-171.
11. Mejia-Arangure JM, Fajardo-Gutierrez A, Flores-Aguilar H et al. Environmental factors contributing to the development of childhood leukemia in children with Down's syndrome. Leukemia 2003;17:1905-1907.
12. Alderton LE, Spector LG, Blair CK et al. Child and maternal household chemical exposure and the risk of acute leukemia in children with Down's syndrome: A report from the Children's Oncology Group. Am J Epidemiol 2006;164:212-221.
13. Mejia-Arangure JM, Fajardo-Gutierrez A, Perez-Saldivar ML et al. Magnetic fields and acute leukemia in children with Down syndrome. Epidemiology 2007;18:158-161.
14. Puumala SE, Ross JA, Olshan AF et al. Reproductive history, infertility treatment, and the risk of acute leukemia in children with Down syndrome: A report from the Children's Oncology Group. Cancer 2007;110:2067-2074.
15. Ross JA, Blair CK, Olshan AF et al. Periconceptional vitamin use and leukemia risk in children with Down syndrome: A Children's Oncology Group study. Cancer 2005;104:405-410.
16. Blair CK, Roesler M, Xie Y et al. Vitamin supplement use among children with Down's syndrome and risk of leukaemia: A Children's Oncology Group (COG) study. Paediatr PerinatEpidemiol 2008;22:288-295.
17. Linabery AM, Olshan AF, Gamis AS et al. Exposure to medical test irradiation and acute leukemia among children with Down syndrome: A report from the Children's Oncology Group. Pediatrics 2006;118:e1499-e1508.
18. Canfield KN, Spector LG, Robison LL et al. Childhood and maternal infections and risk of acute leukaemia in children with Down syndrome: A report from the Children's Oncology Group. Br J Cancer 2004;91:1866-1872.
19. Massey GV, Zipursky A, Chang MN et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood 2006; 107:4606-4613.
20. Gurbuxani S, Vyas P, Crispino JD. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood 2004;103:399-406.
21. James SJ, Pogribna M, Pogribny IP et al. Abnormal folate metabolism and mutation in the methylenetetrahydrofolate reductase gene may be maternal risk factors for Down syndrome. Am J Clin Nutr 1999;70:495-501.
22. Krajinovic M, Lamothe S, Labuda D et al. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood 2004;103:252-257.
23. Sussan TE, Yang A, Li F et al. Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome. Nature 2008;451:73-75.
24. Zorick TS, Mustacchi Z, Bando SY et al. High serum endostatin levels in Down syndrome: Implications for improved treatment and prevention of solid tumours. Eur J Hum Genet 2001;9:811-814.
25. Klusmann JH, Creutzig U, Zimmermann M et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood 2008;111:2991-2998.
26. Pine SR, Guo Q, Yin C et al. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome. Leuk Res 2005;29:1353-1356.
27. Ravindranath Y, Abella E, Krischer JP et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: Experience on Pediatric Oncology Group AML Study 8498. Blood 1992;80: 2210-2214.
28. Lie SO, Jonmundsson G, Mellander L et al. A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: Best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Br J Haematol 1996;94:82-88.
29. Athale UH, Razzouk BI, Raimondi SC et al. Biology and outcome ofchild - hood acute megakaryoblastic leukemia: A single institution's experience. Blood 2001;97:3727-3732.
30. Gamis AS. Acute myeloid leukemia and Down syndrome evolution of modern therapy-state of the art review. Pediatr Blood Cancer 2005;44: 13-20.
31. Lange BJ, Kobrinsky N, Barnard DR et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood 1998;91:608-615.
32. Abildgaard L, Ellebaek E, Gustafsson G et al. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: Data from 56 children treated on NOPHO-AML protocols and a review of the literature. Ann Hematol 2006;85:275-280.
33. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol 2000;110:512-524.
34. KojimaS, Sako M, Kato K et al. Aneffective chemotherapeuticregimenfor acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia 2000;14:786-791.
35. Kudo K, Kojima S, Tabuchi K et al. Prospective study of a irarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: The Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2007;25:5442-5447.
36. Al-Ahmari A, Shah N, Sung L et al. Long-term results ofan ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome. Br J Haematol 2006;133:646-648.
37. Zwaan MC, Reinhardt D, Hitzler J et al. Acute leukemias in children with Down syndrome. Pediatr Clin North Am 2008;55:53-70.
38. Wechsler J, Greene M, McDevitt MA et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002;32: 148 - 152.
39. Mundschau G, Gurbuxani S, Gamis AS et al. Mutagenesis ofGATA1 is an initiating event in Down syndrome leukemogenesis. Blood 2003;101: 4298-4300.
40. Hasle H, Niemeyer CM, Chessells JM et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003;17:277-282.
41. Ahmed M, Sternberg A, Hall G et al. Natural history of GATA1 mutations in Down syndrome. Blood 2004;103:2480-2489.
42. Rainis L, Bercovich D, Strehl S et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 2003;102:981-986.
43. Li Z, Godinho FJ, Klusmann JH et al. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet 2005;37:613-619.
44. Hollanda LM, Lima CS, Cunha AF et al. An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet 2006;38:807-812.
45. Stachura DL, Chou ST, Weiss MJ. Early block to erythromegakaryocytic development conferred by loss of transcription factor GATA-1. Blood 2006;107:87-97.
46. Xu G, Nagano M, Kanezaki R et al. Frequent mutations in the GATA-1 gene in the transientmyeloproliferative disorderofDown syndrome. Blood 2003;102:2960-2968.
47. Bourquin JP, Subramanian A, Langebrake C et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad SciUSA2006;103:3339-3344.
48. Lightfoot J, Hitzler JK, Zipursky A et al. Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down syndrome. Leukemia 2004;18:1617-1623.
49. McElwaine S, Mulligan C, Groet J et al. Microarray transcriptprofiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker. Br J Haematol 2004;125:729-742.
50. Walters DK, Mercher T, Gu TL et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006;10:65-75.
51. Kiyoi H, Yamaji S, Kojima S et al. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non - Down syndrome adults. Leukemia 2007;21:574-576.
52. Klusmann JH, Reinhardt D, Hasle H et al. Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome. Leukemia 2007;21:1584-1587.
53. Norton A, Fisher C, Liu H et al. Analysis ofJAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. Blood 2007;110:1077-1079.
54. Malinge S, Ragu C, Della-Valle V et al. Activating mutations in human acute megakaryoblastic leukemia. Blood 2008;112:4220-4226.
55. Pui CH, Raimondi SC, Borowitz MJ et al. Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia. J Clin Oncol 1993;11:1361-1367.
56. Dördelmann M, Schrappe M, Reiter A et al. Down's syndrome in childhood acute lymphoblastic leukemia: Clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group.Leukemia 1998;12:645-651.
57. Chessells JM, Harrison G, Richards SM et al. Down's syndrome and acute lymphoblastic leukaemia: Clinical features and response to treatment. Arch Dis Child 2001;85:321-325.
58. Zeller B, Gustafsson G, Forestier E et al. Acute leukaemia in children with Down syndrome: A population-based Nordic study. Br J Haematol 2005;128:797-804.
59. Bassal M, La MK, Whitlock JA et al. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer 2005;44:21-28.
60. Whitlock JA, Sather HN, Gaynon P et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 2005;106:4043-4049.
61. Arico M, Ziino O, Valsecchi MG et al. Acute lymphoblastic leukemia and Down syndrome: Presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Cancer 2008;113:515-521.
62. Forestier E, Izraeli S, Beverloo B et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: AniBFM-SG study. Blood 2008;111:1575-1583.
63. Maloney KW, Carroll WL, Carroll A et al. Comparison of the biology of Down syndrome (DS) acute lymphoblastic leukemia (ALL) and non-DS ALL: Children's Oncology Group study P9900. J Clin Oncol 2008;26(15 suppl):10003a.
64. Bercovich D, Ganmore I, Scott LM et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008; 372:1484-1492.
65. James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434: 1144-1148.
66. Hastings C, Whitlock JA, La M et al. Improved outcome of children with Down syndrome and high risk acute lymphocytic leukemia: A report of CCG-1961. Blood 2007;110:586a.
67. Whitlock JA. Down syndrome and acute lymphoblastic leukaemia. Br J Haematol 2006;135:595-602.
68. Zwaan CM, Kaspers GJ, Pieters R et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 2002;99:245-251.
69. Taub JW, Huang X, Matherly LH et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: Differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 1999;94:1393-1400.
70. Ge Y, Dombkowski AA, LaFiura KM et al. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocyticleukemia Blood 2006;107:1570-1581.
71. Taub JW, Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer 2005;44:33-39.
72. Ge Y, Jensen TL, Stout ML et al. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res 2004;64: 728-735.
73. Krischer JP, Epstein S, Cuthbertson DD et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Groupexperience. J Clin Oncol 1997;15:1544-1552.
74. O'Brien MM, Taub JW, Chang MN et al. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: A report from the Children's OncologyGroupStudy POG 9421. JClinOncol2008;26:414-420.
75. Morawiec Z, Janik K, Kowalski M et al. DNA damage and repair in children with Down's syndrome. MutatRes 2008;637:118-123.
76. Creutzig U, Diekamp S, Zimmermann M et al. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer 2007;48:651-662.
77. Frost BM, Gustafsson G, Larsson R et al. Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: An explanation to differences in clinical outcome? Leukemia 2000;14:943-944.
78. Kalwinsky DK, Raimondi SC, Bunin NJ et al. Clinical and biological characteristics ofacute lymphocyticleukemiainchildrenwithDownsyndrome. Am J Med GenetSuppl 1990;7:267-271.
79. Garre ML, Relling MV, Kalwinsky D et al. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr1987;111:606-612.
80. Peeters M, Poon A. Down syndrome and leukemia: Unusual clinical aspects and unexpected methotrexate sensitivity. Eur J Pediatr 1987;146: 416-422.
81. Blatt J, Albo V, Prin W et al. Excessive chemotherapy-related myelotoxicity in children with Down syndrome and acute lymphoblastic leukaemia. Lancet1986;2:914.
82. Zhang L, Taub JW, Williamson M et al. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: Relationship to immunophenotype and ploidy. Clin Cancer Res 1998;4:2169-2177.
83. Lonnerholm G, Frost BM, Soderhall S et al. Vincristine pharmacokinetics in childrenwithDownsyndrome. PediatrBloodCancer2009;52:123-125.
84. Valle M, Plon SE, Rabin KR. Differential in vitro cytotoxicity does notexplain increased host toxicities from chemotherapy in Down syndrome acute lymphoblastic leukemia. Leuk Res 2009;33:336-339.
85. Gregory L, Williams R, Thompson E. Leucocyte function in Down's syndrome and acute leukaemia. Lancet1972;1:1359-1361.
86. SpinaCA, SmithD, KornEet al. Altered cellular immune functions inpatients with Down's syndrome. Am J Dis Child 1981;135:251-255.
87. Avanzini MA, Monafo V, De Amici M et al. Humoral immunodeficiencies in Down syndrome: Serum IgG subclass and antibody response to hepatitis B vaccine. Am J Med GenetSuppl 1990;7:231-233.
88. Ugazio AG, Maccario R, Notarangelo LD et al. Immunology of Down syndrome: A review. Am J Med GenetSuppl 1990;7:204-212.
89. Craze JL, Harrison G, Wheatley K et al. Improved outcome of acute my-eloid leukaemia in Down's syndrome. Arch Dis Child 1999;81:32-37.
90. LieSO, AbrahamssonJ, ClausenNet al. Long-termresultsinchildrenwith AML: NOPHO-AML Study Group-report of three consecutive trials. Leukemia 2005;19:2090-2100.
91. Ravindranath Y, Yeager AM, Chang MN et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996;334:1428-1434.